Semaglutide Interactions: What the Literature Covers on Alcohol, Caffeine, Food and Other Compounds (With Cagrilintide Context)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed and licensed as a prescription medicine for type 2 diabetes and for chronic weight management, and reviews have described its development pathway and clinical profile in both indications (PMID 34706925, PMID 34942372). Questions about combining it with alcohol, caffeine, meals, fasting schedules or other compounds therefore sit inside a regulated prescribing context. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician for any question about whether a medicine, beverage or supplement is appropriate in an individual case.

What the Interaction Evidence Base Actually Covers

"Interaction" is used loosely in public discussion. In the published literature it usually means one of three distinct things: a pharmacokinetic interaction (one substance changes the absorption, distribution, metabolism or elimination of another), a pharmacodynamic interaction (two substances act on overlapping systems and the combined effect differs from either alone), or a tolerability overlap (two substances produce similar unwanted effects that may compound).

For semaglutide, the clinical pharmacokinetic literature has been collated in a 2024 systematic review that summarised absorption, distribution, metabolism and elimination data across subcutaneous and oral formulations and across studied populations (PMID 38952487). That review is the natural reference point for pharmacokinetic questions, because it describes the parameters any proposed interaction would have to move.

Where a dedicated interaction study exists, this page reports it. Where one does not, that gap is stated plainly, and the reasoning researchers use in its absence is labelled explicitly as mechanistic reasoning rather than as a finding.

Semaglutide and Alcohol: What Studies Report

Alcohol is the one "combination" question with direct randomised evidence, because GLP-1 receptor agonists have been tested as candidate treatments for alcohol use disorder rather than merely studied for safety alongside drinking.

A randomised clinical trial published in JAMA Psychiatry in 2025 evaluated once-weekly semaglutide in adults with alcohol use disorder and reported effects on alcohol consumption outcomes compared with placebo (PMID 39937469). A subsequent randomised, double-blind, placebo-controlled trial published in The Lancet compared once-weekly semaglutide with placebo in patients who had both alcohol use disorder and comorbid obesity, examining alcohol-related endpoints in a population selected for that overlap (PMID 42070571).

Two points matter when reading these. First, both were trials of semaglutide as an intervention in diagnosed alcohol use disorder — the study populations were people with a clinical alcohol diagnosis, not people drinking socially while taking semaglutide for another indication, so researchers have cautioned that generalisation beyond the enrolled populations is not automatic (PMID 42070571). Second, neither trial was designed as a pharmacokinetic drug–alcohol interaction study; they measured behavioural and consumption outcomes, not whether alcohol alters semaglutide exposure or vice versa.

The mechanistic rationale researchers cite for testing GLP-1 agonists in substance-related conditions comes from preclinical work: a 2020 study reported that semaglutide lowered body weight in rodents through distributed neural pathways rather than a single hypothalamic site, implicating central circuits that also participate in reward processing (PMID 32213703). A 2025 narrative review extended that line of reasoning to binge eating disorder, surveying the neurobiological mechanisms proposed for GLP-1 receptor agonists in disordered consummatory behaviour (PMID 41303457). This is mechanistic reasoning about why alcohol and food reward endpoints were studied together — it is not evidence of a safety interaction in either direction.

Semaglutide and Caffeine: No Dedicated Interaction Study

Among the verified literature summarised here, no trial examined semaglutide together with caffeine, coffee or caffeinated energy drinks. There is no reported finding to summarise, and no study-derived statement about the combination can be made.

Mechanistic reasoning (labelled as such, not a finding): researchers evaluating a hypothetical caffeine question would typically ask whether the two share an elimination pathway, and whether either changes gastric handling of the other. The clinical pharmacokinetics of semaglutide, including its metabolism and elimination routes, were systematically reviewed in 2024, and that review is the appropriate source for the parameters such an analysis would use (PMID 38952487). Separately, trials of semaglutide have measured gastric emptying as an endpoint, which is the mechanism most often invoked when people ask whether a GLP-1 agonist changes how quickly an orally ingested substance reaches the small intestine (PMID 39082206). Neither observation constitutes a caffeine interaction result.

Food, Appetite and Energy Intake: What Studies Report

The food question is the best-characterised, because reduced energy intake is a measured pharmacodynamic effect rather than an incidental interaction.

A randomised trial in subjects with obesity reported that 12 weeks of once-weekly semaglutide 1.0 mg reduced ad libitum energy intake by 24% versus placebo, with accompanying changes in appetite ratings, control of eating and body weight (PMID 28266779). The study also assessed food preference, meaning the trial examined not only how much participants ate but what they reported wanting to eat (PMID 28266779).

A later randomised controlled trial of oral semaglutide 50 mg in adults living with obesity reported effects on energy intake, appetite and control of eating, and measured gastric emptying in the same protocol (PMID 39082206). Reviews of semaglutide for obesity have placed these appetite and intake findings alongside the weight outcomes seen in the larger clinical programme (PMID 34942372, PMID 35175229).

On fasting windows, intermittent fasting protocols, ketogenic diets or specific meal timing: no verified trial examined semaglutide against a structured fasting or dietary pattern as an interaction variable. Reviews describe semaglutide as studied within trial protocols that included lifestyle components, but the comparative question — whether one eating pattern changes semaglutide's effects — was not the subject of the trials cited here (PMID 35175229).

Oral Versus Subcutaneous Formulation: Why Dosing Conditions Are Studied

Interaction questions differ by formulation. Subcutaneous semaglutide bypasses the gut entirely at the point of administration, whereas oral semaglutide must be absorbed across the gastric mucosa, and the 2024 systematic review of semaglutide pharmacokinetics addressed both routes and the factors influencing their exposure profiles (PMID 38952487). This is why a randomised trial of oral semaglutide 50 mg specifically included gastric emptying among its endpoints (PMID 39082206). Anyone prescribed an oral formulation receives product-specific administration conditions from the prescribing clinician and the approved product labelling; those conditions are not something this page restates or interprets.

Cagrilintide Context: Combination Research

Cagrilintide is a long-acting amylin analogue studied in combination with semaglutide rather than as a stand-alone consumer compound. A 2025 trial published in the New England Journal of Medicine evaluated coadministered cagrilintide and semaglutide in adults with overweight or obesity, reporting body-weight outcomes for the combination (PMID 40544433). That is a deliberate, trial-designed combination of two investigational or licensed agents under clinical supervision — not an interaction discovered after the fact, and not a template for informal combining. Both components in that research programme are prescription or investigational medicines, and questions about either belong with a prescribing clinician.

Other Commonly Asked Combinations

Several combination questions recur. For each, the honest answer in the verified literature is as follows:

• Other glucose-lowering medicines: reviews of semaglutide in type 2 diabetes and obesity described its use within broader treatment contexts, but the specific combination pharmacology sits in prescribing information rather than in the trials summarised here (PMID 34706925).
• Cardiovascular medicines: a prespecified analysis of the SELECT trial examined semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure — a population typically on multiple background therapies — and reported outcomes in that subgroup (PMID 39181597). That is background-therapy context, not a dedicated interaction analysis.
• Supplements, nootropics and other peptides: no verified trial examined semaglutide alongside any dietary supplement or research peptide. No finding exists to report.
• Stimulant-containing products: as with caffeine, no verified trial examined the combination.

Gastrointestinal Tolerability and Overlap Effects: What Studies Report

The practical reason interaction questions arise is tolerability overlap. Reviews of semaglutide for chronic weight management have described gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — as the most commonly reported adverse events in the clinical programme, generally occurring during dose escalation (PMID 34706925, PMID 34942372). Reviews of semaglutide in overweight and obesity reported the same adverse-event pattern alongside cardiometabolic risk outcomes (PMID 35175229). In the coadministration trial of cagrilintide and semaglutide, gastrointestinal events were likewise the adverse events reported most frequently (PMID 40544433). Because alcohol and some beverages independently affect the gastrointestinal tract, researchers describe this as an overlap-of-effects question — but the verified alcohol trials measured consumption outcomes, not gastrointestinal interaction endpoints (PMID 39937469).

Interaction Topics at a Glance

Limits of This Evidence

Three limitations shape every statement above. The alcohol trials enrolled people with a diagnosed alcohol use disorder, so their findings describe that population rather than drinking behaviour in general (PMID 39937469). The food and appetite trials used controlled laboratory meal paradigms over defined periods, which capture intake precisely but not necessarily long-term everyday eating (PMID 28266779). And the pharmacokinetic picture was assembled from a systematic review of existing studies, which can only summarise the interactions that were actually investigated (PMID 38952487). Absence of a published interaction study is not the same as evidence of no interaction, and the formal interaction section of approved product labelling — maintained by regulators and the manufacturer — remains the document a prescribing clinician works from.

References

• Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity (Diabetes, Obesity & Metabolism, 2017)
• Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial (Lancet, 2026)
• Semaglutide for the treatment of obesity (Trends in Cardiovascular Medicine, 2023)
• Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial (Diabetes, Obesity & Metabolism, 2024)
• Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial (Lancet, 2024)
• Semaglutide lowers body weight in rodents via distributed neural pathways (JCI Insight, 2020)
• Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial (JAMA Psychiatry, 2025)
• Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity (Current Opinion in Cardiology, 2022)
• Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine, 2025)
• Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review (International Journal of Molecular Sciences, 2025)
• Wegovy (semaglutide): a new weight loss drug for chronic weight management (Journal of Investigative Medicine, 2022)
• Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)